{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:08:24Z","timestamp":1790662104789,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.trim.2024.102147","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:54:32Z","timestamp":1731689672000},"page":"102147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Cyclosporine: Immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug"],"prefix":"10.1016","volume":"88","author":[{"given":"Razan","family":"Alqadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Alqumia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim S.","family":"Alhomoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alhowail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Aldubayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdoon A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Alhmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riaz A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2024.102147_bb0005","series-title":"Cyclosporine Biosynthesis in Tolypocladium inflatum Benefits Fungal Adaptation to the Environment","volume":"9(5)","author":"Yang","year":"2018"},{"issue":"1\u20132","key":"10.1016\/j.trim.2024.102147_bb0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.imlet.2011.06.010","article-title":"The effects of cyclosporine A and azathioprine on human T cells activated by different costimulatory signals","volume":"140","author":"Leitner","year":"2011","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.trim.2024.102147_bb0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2016.01.056","article-title":"Reformulating cyclosporine A (CsA): more than just a life cycle management strategy","volume":"225","author":"Guada","year":"2016","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0020","first-page":"80","article-title":"Indications for therapeutic activity of cyclosporine","volume":"51","author":"Mourani","year":"2003","journal-title":"J. Med. Liban."},{"issue":"Suppl. 2","key":"10.1016\/j.trim.2024.102147_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/vr.102484","article-title":"Ciclosporin 10 years on: indications and efficacy","volume":"174","author":"Forsythe","year":"2014","journal-title":"Vet. Rec."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5125\/jkaoms.2023.49.6.311","article-title":"S. M. Kim. Review of two immunosuppressants: tacrolimus and cyclosporine","volume":"49","author":"Lee","year":"2023","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","article-title":"The many faces of calcineurin inhibitor toxicity-what the FK?","volume":"27","author":"Farouk","year":"2020","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.21037\/atm.2019.12.117","article-title":"Immunosuppressive strategies in lung transplantation","volume":"8","author":"Chung","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-3046.2005.00436.x","article-title":"Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function","volume":"10","author":"Kalyoncu","year":"2006","journal-title":"Pediatr. Transplant."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0050","first-page":"139","article-title":"Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients","volume":"11","author":"Li","year":"2006","journal-title":"Eur. J. Med. Res."},{"issue":"21","key":"10.1016\/j.trim.2024.102147_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214832","article-title":"Old and new calcineurin inhibitors in lupus nephritis","volume":"10","author":"Ponticelli","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/17425255.2011.544249","article-title":"Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions","volume":"7","author":"Christians","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.trim.2024.102147_bb0065","series-title":"Immunosuppressive Agents-Effects on the Cardiovascular System and Selected Metabolic Aspects: A Review","volume":"12(21)","author":"Opa\u0142ka","year":"2023"},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8040094","article-title":"Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates","volume":"8","author":"Saiz-Rodr\u00edguez","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.trim.2024.102147_bb0075","doi-asserted-by":"crossref","unstructured":"Sourced from RCSB, PDB: CYP3A4, https:\/\/doi.org\/10.2210\/pdb1W0E\/pdb; and CYP3A5, https:\/\/doi.org\/10.2210\/pdb6MJM\/pdb, accessed on October 20, 2024.","DOI":"10.2210\/pdb6mjm\/pdb"},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5487\/TR.2010.26.3.163","article-title":"Use of antioxidants to prevent cyclosporine a toxicity","volume":"26","author":"Lee","year":"2010","journal-title":"Toxicol. Res."},{"issue":"12","key":"10.1016\/j.trim.2024.102147_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210291","article-title":"The effect of calcineurin inhibitors on MMPs activity in heart and their side effects\u2014a review of literature","volume":"24","author":"Sur\u00f3wka","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trim.2024.102147_bb0090","series-title":"Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics","volume":"14(9)","author":"Brunet","year":"2022"},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v16.i5.20","article-title":"Microemulsions: an overview and pharmaceutical applications","volume":"16","author":"Tenjarla","year":"1999","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"13","key":"10.1016\/j.trim.2024.102147_bb0100","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2165\/00003495-200161130-00006","article-title":"Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation","volume":"61","author":"Dunn","year":"2001","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0105","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00019053-199814060-00009","article-title":"Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation","volume":"14","author":"Coukell","year":"1998","journal-title":"PharmacoEconomics"},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/0250-474X.107082","article-title":"Production of cyclosporine A by submerged fermentation from a local isolate of Penicillium fellutanum","volume":"74","author":"Anjum","year":"2012","journal-title":"Indian J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.trim.2024.102147_bb0115","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1002\/eji.1830231205","article-title":"Cyclosporin A inhibits T cell receptor-induced interleukin-2 synthesis of human T lymphocytes by selectively preventing a transmembrane signal transduction pathway leading to sustained activation of a protein kinase C isoenzyme, protein kinase C-beta","volume":"23","author":"Szamel","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.trim.2024.102147_bb0120","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbrc.2008.09.005","article-title":"Effect of cyclosporine on parasitemia and survival of plasmodium berghei infected mice","volume":"376","author":"Bobbala","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.trim.2024.102147_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.828078","article-title":"Emerging roles of cyclophilin A in regulating viral cloaking","volume":"13","author":"Mamatis","year":"2022","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0135","doi-asserted-by":"crossref","DOI":"10.4161\/psb.22734","article-title":"Cyclophilins: proteins in search of function","volume":"8","author":"Kumari","year":"2013","journal-title":"Plant Signal. Behav."},{"issue":"22","key":"10.1016\/j.trim.2024.102147_bb0140","doi-asserted-by":"crossref","first-page":"19294","DOI":"10.1074\/jbc.M009379200","article-title":"Lack of abundance of cytoplasmic cyclosporin A-binding protein renders free-living Leishmania donovani resistant to cyclosporin A","volume":"276","author":"Dutta","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trim.2024.102147_bb0145","first-page":"12","article-title":"Current status regarding immunosuppressive treatment in patients after renal","volume":"24","author":"Szumilas","year":"2023","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-3083.2006.01877.x","article-title":"Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis","volume":"21","author":"Hijnen","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0155","first-page":"493","article-title":"Cyclosporine in transplantation - a history of converging timelines","volume":"25","author":"Colombo","year":"2011","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01211-18","article-title":"Cyclosporine biosynthesis in Tolypocladium inflatum benefits fungal adaptation to the environment","volume":"9","author":"Yang","year":"2018","journal-title":"mBio"},{"issue":"2\u20133","key":"10.1016\/j.trim.2024.102147_bb0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.etp.2014.11.008","article-title":"Cytotoxic and genotoxic effects of high concentrations of the immunosuppressive drugs cyclosporine and tacrolimus in MRC-5 cells","volume":"67","author":"Cili\u00e3o","year":"2015","journal-title":"Exp. Toxicol. Pathol."},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0175","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.rcl.2023.04.010","article-title":"Immunosuppressive therapy in solid organ transplantation: primer for radiologists and potential complications","volume":"61","author":"Tammisetti","year":"2023","journal-title":"Radiol. Clin. North Am."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0180","article-title":"Acute cyclosporine overdose: a systematic review","volume":"6","author":"Ershad","year":"2023","journal-title":"Med. Cl\u00edn. Pr\u00e1ct."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0185","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1038\/s41598-024-57300-x","article-title":"Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-\u03b1, NF-\u03baB, and Bax","volume":"14","author":"Abd-Eldayem","year":"2024","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.trim.2024.102147_bb0190","first-page":"515","article-title":"Insights into chronic cyclosporine nephrotoxicity","volume":"34","author":"Bennett","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1 Pt 2","key":"10.1016\/j.trim.2024.102147_bb0195","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/01.HYP.35.1.360","article-title":"Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes","volume":"35","author":"Mervaala","year":"2000","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.transproceed.2003.11.071","article-title":"The renin-angiotensin system and endothelial nitric oxide synthase gene polymorphisms and cyclosporine toxicity in renal transplant patients","volume":"36","author":"Ozdemir","year":"2004","journal-title":"Transplant. Proc."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0205","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1389200023337964","article-title":"Interaction of cyclosporine A and the renin-angiotensin system; new perspectives","volume":"3","author":"Lassila","year":"2002","journal-title":"Curr. Drug Metab."},{"issue":"4 Suppl 1","key":"10.1016\/j.trim.2024.102147_bb0210","first-page":"51","article-title":"Pathogenetic mechanisms of nephrotoxicity: insights into cyclosporine nephrotoxicity","volume":"17","author":"Humes","year":"1985","journal-title":"Transplant. Proc."},{"issue":"9","key":"10.1016\/j.trim.2024.102147_bb0215","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1093\/ndt\/gfq135","article-title":"A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits","volume":"25","author":"Etienne","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2 Suppl","key":"10.1016\/j.trim.2024.102147_bb0220","doi-asserted-by":"crossref","first-page":"234s","DOI":"10.1016\/j.transproceed.2004.01.011","article-title":"Nephrotoxic aspects of cyclosporine","volume":"36","author":"Cattaneo","year":"2004","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2024.102147_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2023.153544","article-title":"Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity","volume":"492","author":"Yu","year":"2023","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0230","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00007691-199103000-00011","article-title":"Comparison of nonspecific radioimmunoassay, high-performance liquid chromatography, and fluorescence polarization immunoassay for cyclosporine monitoring in renal transplantation","volume":"13","author":"Lee","year":"1991","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0235","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jcla.1860090405","article-title":"Analysis of whole-blood cyclosporin G by liquid chromatography in renal transplant recipients","volume":"9","author":"McBride","year":"1995","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.trim.2024.102147_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.742419","article-title":"T-lymphocyte subsets alteration, infection and renal outcome in advanced chronic kidney disease","volume":"8","author":"Xiong","year":"2021","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0245","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2125.1990.tb03796.x","article-title":"A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation","volume":"30","author":"Lindholm","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0250","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/ALN.0b013e3182a05bd3","article-title":"Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics","volume":"119","author":"Meissner","year":"2013","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0255","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00606661","article-title":"Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects","volume":"31","author":"Grevel","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"13","key":"10.1016\/j.trim.2024.102147_bb0260","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM198909283211301","article-title":"A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn\u2019s disease","volume":"321","author":"Brynskov","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0265","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2005090922","article-title":"Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial","volume":"17","author":"Hoyer","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2141.1983.tb02067.x","article-title":"Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes","volume":"54","author":"Atkinson","year":"1983","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0275","first-page":"321","article-title":"The efficacy of cyclosporin-a in the treatment of Beh\u00e7et\u2019s disease","volume":"25","author":"Atmaca","year":"1994","journal-title":"Ophthalmic Surg."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0280","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/bjo.74.6.350","article-title":"Ocular penetration of cyclosporin A. III: the human eye","volume":"74","author":"BenEzra","year":"1990","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0285","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archderm.1992.01680160070006","article-title":"Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy","volume":"128","author":"Burns","year":"1992","journal-title":"Arch. Dermatol."},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00679794","article-title":"Penetration of cyclosporin into synovial fluid in rheumatoid arthritis","volume":"37","author":"van Rijthoven","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0295","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0009-9120(95)00037-3","article-title":"Alternative cyclosporine metabolic pathways and toxicity","volume":"28","author":"Christians","year":"1995","journal-title":"Clin. Biochem."},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0300","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.apsb.2016.07.012","article-title":"An update on the role of intestinal cytochrome P450 enzymes in drug disposition","volume":"6","author":"Xie","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0305","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2125.1992.tb04098.x","article-title":"Cyclosporin metabolism by human gastrointestinal mucosal microsomes","volume":"33","author":"Webber","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.trim.2024.102147_bb0310","article-title":"Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions","volume":"13","author":"Kong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trim.2024.102147_bb0315","series-title":"The Pharmacokinetic and Absolute Bioavailability of Cyclosporine (Atopica for Cats(\u00ae)) in Cats","volume":"10(6)","author":"Kong","year":"2023"},{"issue":"Pt 2","key":"10.1016\/j.trim.2024.102147_bb0320","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1107\/S0907444910051905","article-title":"Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin)","volume":"67","author":"Kuglstatter","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0325","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00431-011-1633-0","article-title":"Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome","volume":"171","author":"Ushijima","year":"2012","journal-title":"Eur. J. Pediatr."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0330","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/FTD.0000000000000442","article-title":"Effect of age and allele variants of CYP3A5, CYP3A4, and POR genes on the pharmacokinetics of cyclosporin A in pediatric renal transplant recipients from Serbia","volume":"39","author":"Cvetkovi\u0107","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.trim.2024.102147_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.635165","article-title":"Pharmacokinetic and pharmacodynamic considerations in relation to calcineurin usage in elderly kidney transplant recipients","volume":"12","author":"Cossart","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1 Pt 2","key":"10.1016\/j.trim.2024.102147_bb0340","first-page":"1704","article-title":"Effect of age on cyclosporine pharmacokinetics in marrow transplant recipients","volume":"19","author":"Yee","year":"1987","journal-title":"Transplant. Proc."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0345","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2165\/00003088-199324060-00004","article-title":"Cyclosporin clinical pharmacokinetics","volume":"24","author":"Fahr","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0350","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002512-199915030-00003","article-title":"Cyclosporin pharmacokinetics in the elderly","volume":"15","author":"Kovarik","year":"1999","journal-title":"Drugs Aging"},{"issue":"6226","key":"10.1016\/j.trim.2024.102147_bb0355","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/339625a0","article-title":"Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes","volume":"339","author":"Shi","year":"1989","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0360","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1582-4934.2004.tb00321.x","article-title":"Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease","volume":"8","author":"Kountouras","year":"2004","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0365","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0014-2999(94)90345-X","article-title":"The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine TH2-type T cells","volume":"260","author":"Schmidt","year":"1994","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0370","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/jvp.12280","article-title":"Effects of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a 12-h dosing interval","volume":"39","author":"Fellman","year":"2016","journal-title":"J. Vet. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0375","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1620\/tjem.236.289","article-title":"Successful treatment of TAFRO syndrome, a variant of multicentric castleman\u2019s disease, with cyclosporine A: possible pathogenetic contribution of Interleukin-2","volume":"236","author":"Konishi","year":"2015","journal-title":"Tohoku J. Exp. Med."},{"issue":"11","key":"10.1016\/j.trim.2024.102147_bb0380","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147683","article-title":"Calcineurin inhibitors suppress acute graft-versus-host disease via NFAT-independent inhibition of T cell receptor signaling","volume":"131","author":"Otsuka","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0385","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.trim.2024.102147_bb0390","first-page":"S191","article-title":"The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses","volume":"153","author":"Pettipher","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0395","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04051.x","article-title":"Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help","volume":"159","author":"Heidt","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0400","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14653240802129885","article-title":"Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function","volume":"10","author":"Lin","year":"2008","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension","volume":"25","author":"Hoorn","year":"2012","journal-title":"J. Nephrol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0410","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0090-6980(92)90035-R","article-title":"Protection of glomerular filtration rate by the thromboxane receptor antagonist L655,240 during low dose cyclosporine administration","volume":"43","author":"Bunke","year":"1992","journal-title":"Prostaglandins"},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0415","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4103\/1735-3327.192276","article-title":"Effect of cyclosporin A and angiotensin II on cytosolic calcium levels in primary human gingival fibroblasts","volume":"13","author":"Supraja","year":"2016","journal-title":"Dent. Res. J."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0420","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02659092","article-title":"Calcium antagonists prevent cyclosporin a-induced nephrotoxicity","volume":"2","author":"Dawidson","year":"1993","journal-title":"InflammoPharmacology"},{"issue":"1 Pt 2","key":"10.1016\/j.trim.2024.102147_bb0425","first-page":"1695","article-title":"Pharmacodynamic assays of the immunosuppressive action of cyclosporine therapy in transplant recipients","volume":"19","author":"Kahan","year":"1987","journal-title":"Transplant. Proc."},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0430","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40262-015-0339-2","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressants in allogeneic haematopoietic cell transplantation: part I","volume":"55","author":"McCune","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0435","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s13346-019-00650-1","article-title":"Recent advances in cyclosporine drug delivery: challenges and opportunities","volume":"9","author":"Patel","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0440","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/TP.0b013e3182590d8f","article-title":"In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function","volume":"94","author":"Miroux","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2024.102147_bb0445","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.phrs.2017.11.029","article-title":"Cardiovascular and renal interactions between cyclosporine and NSAIDs: underlying mechanisms and clinical relevance","volume":"129","author":"El-Yazbi","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0450","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0733-8635(18)30052-4","article-title":"Cyclosporine: what clinicians need to know","volume":"13","author":"Koo","year":"1995","journal-title":"Dermatol. Clin."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0455","doi-asserted-by":"crossref","first-page":"454","DOI":"10.5021\/ad.2015.27.4.454","article-title":"Cyclosporine-induced posterior reversible encephalopathy syndrome in a patient with pemphigus vulgaris","volume":"27","author":"Park","year":"2015","journal-title":"Ann. Dermatol."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0460","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1124\/mi.4.2.7","article-title":"Biochemical mechanisms of cyclosporine neurotoxicity","volume":"4","author":"Serkova","year":"2004","journal-title":"Mol. Interv."},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0465","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/brainsci3031325","article-title":"Molecular dissection of cyclosporin A\u2019s neuroprotective effect reveals potential therapeutics for ischemic brain injury","volume":"3","author":"Kawakami","year":"2013","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0470","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/0886022X.2022.2083974","article-title":"Arteriolar hyalinosis and renal outcomes in patients with immunoglobulin A nephropathy","volume":"44","author":"Shen","year":"2022","journal-title":"Ren. Fail."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0475","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5527\/wjn.v1.i2.35","article-title":"Collapsing focal segmental glomerulosclerosis: current concepts","volume":"1","author":"Mubarak","year":"2012","journal-title":"World J. Nephrol."},{"issue":"10","key":"10.1016\/j.trim.2024.102147_bb0480","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.12691216","article-title":"Slow rise in serum creatinine level in a kidney transplant recipient 3 years post-transplant","volume":"12","author":"Bia","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.trim.2024.102147_bb0485","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.clinthera.2004.09.012","article-title":"Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study","volume":"26","author":"Ghiggeri","year":"2004","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0490","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ehf2.12585","article-title":"Incidence of end-stage renal disease after heart transplantation and effect of its treatment on survival","volume":"7","author":"Roest","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0495","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ki.1995.311","article-title":"Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy","volume":"48","author":"Young","year":"1995","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0500","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.3390\/ijms15058979","article-title":"Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model","volume":"15","author":"Sereno","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0505","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/01.HYP.0000085195.38870.44","article-title":"Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension","volume":"42","author":"Nishiyama","year":"2003","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0510","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0002-9440(10)62984-7","article-title":"Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition","volume":"167","author":"Slattery","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.trim.2024.102147_bb0515","doi-asserted-by":"crossref","first-page":"F596","DOI":"10.1152\/ajprenal.00365.2015","article-title":"TGF-\u03b2 signaling in the kidney: profibrotic and protective effects","volume":"310","author":"Sureshbabu","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"11","key":"10.1016\/j.trim.2024.102147_bb0520","article-title":"Frequency and risk factors of cyclosporine-induced neurotoxicity in allogeneic stem cell transplant recipients","volume":"13","author":"Danish","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.trim.2024.102147_bb0525","series-title":"Tremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature","first-page":"301","volume":"23(4)","author":"Wagle Shukla","year":"2023"},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0530","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00247-001-0628-9","article-title":"CT and MRI findings of cyclosporine-related encephalopathy and hypertensive encephalopathy","volume":"32","author":"Yamamoto","year":"2002","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.trim.2024.102147_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1140732","article-title":"Case report: cyclosporine A-induced extrapyramidal syndrome following hematopoietic stem cell transplantation","volume":"14","author":"Al-Amrani","year":"2023","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.trim.2024.102147_bb0540","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/088307389801300706","article-title":"Cyclosporin A acute encephalopathy and seizure syndrome in childhood: clinical features and risk of seizure recurrence","volume":"13","author":"Gleeson","year":"1998","journal-title":"J. Child Neurol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0545","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ejpn.2015.02.003","article-title":"Age-dependent vulnerability of cyclosporine-associated encephalopathy in children","volume":"19","author":"Chen","year":"2015","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.trim.2024.102147_bb0550","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fneur.2020.00463","article-title":"Posterior reversible encephalopathy syndrome (PRES): pathophysiology and neuro-imaging","volume":"11","author":"Anderson","year":"2020","journal-title":"Front. Neurol."},{"issue":"1\u20133","key":"10.1016\/j.trim.2024.102147_bb0555","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejphar.2010.05.035","article-title":"Cyclosporin A induces hyperpermeability of the blood-brain barrier by inhibiting autocrine adrenomedullin-mediated up-regulation of endothelial barrier function","volume":"644","author":"Dohgu","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0560","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0272-6386(12)80300-3","article-title":"Severe neurologic toxicity induced by cyclosporine A in three renal transplant patients","volume":"18","author":"Palmer","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.trim.2024.102147_bb0565","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fimmu.2018.00141","article-title":"A role for the Krebs cycle intermediate citrate in metabolic reprogramming in innate immunity and inflammation","volume":"9","author":"Williams","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0570","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41409-022-01598-6","article-title":"Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study","volume":"57","author":"H\u00e9ritier","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0575","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/00007890-198705000-00006","article-title":"The effect of zero HLA class I and II mismatching in cyclosporine-treated kidney transplant patients","volume":"43","author":"Cicciarelli","year":"1987","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0580","article-title":"Acute cyclosporine overdose: a systematic review","volume":"6","author":"Ershad","year":"2023","journal-title":"Med. Cl\u00edn. Pr\u00e1ct."},{"issue":"20","key":"10.1016\/j.trim.2024.102147_bb0585","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2174\/0929867327666201006153202","article-title":"Cyclosporine A: chemistry and toxicity - a review","volume":"28","author":"Patocka","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0590","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2174\/157488408785747674","article-title":"Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives","volume":"3","author":"Magnasco","year":"2008","journal-title":"Curr. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0595","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.TP.0000074360.62032.39","article-title":"Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune maintenance regimen study","volume":"76","author":"Oberbauer","year":"2003","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0600","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12016-016-8582-3","article-title":"The use of cyclosporine A in rheumatology: a 2016 comprehensive review","volume":"52","author":"Chighizola","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0605","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/j.1875-9114.1996.tb03639.x","article-title":"Cyclosporine neurotoxicity","volume":"16","author":"Hauben","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0610","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s004150050360","article-title":"Cyclosporine neurotoxicity: a review","volume":"246","author":"Gijtenbeek","year":"1999","journal-title":"J. Neurol."},{"issue":"2, Supplement","key":"10.1016\/j.trim.2024.102147_bb0615","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1016\/j.transproceed.2004.01.091","article-title":"Therapeutic drug monitoring of cyclosporine: 20 years of progress","volume":"36","author":"Kahan","year":"2004","journal-title":"Transplant. Proc."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0620","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.transproceed.2009.06.155","article-title":"Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation","volume":"41","author":"Rodrigo","year":"2009","journal-title":"Transplant. Proc."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0625","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.V461306","article-title":"Efficacy of area under the curve cyclosporine monitoring in renal transplantation","volume":"4","author":"Meyer","year":"1993","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0630","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1681\/ASN.V124828","article-title":"Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study","volume":"12","author":"Mahalati","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0635","first-page":"119","article-title":"Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation","volume":"65","author":"Vavi\u0107","year":"2008","journal-title":"Vojnosanit. Pregl."},{"issue":"6","key":"10.1016\/j.trim.2024.102147_bb0640","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.TP.0000089006.00653.64","article-title":"Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion","volume":"76","author":"Thervet","year":"2003","journal-title":"Transplantation"},{"issue":"7\u20138","key":"10.1016\/j.trim.2024.102147_bb0645","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/S0041-1345(01)02336-3","article-title":"C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients","volume":"33","author":"Citterio","year":"2001","journal-title":"Transplant. Proc."},{"issue":"12","key":"10.1016\/j.trim.2024.102147_bb0650","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1097\/01.TP.0000068868.01424.61","article-title":"Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients","volume":"75","author":"Cole","year":"2003","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.trim.2024.102147_bb0655","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/01.TP.0000085046.39523.D5","article-title":"C2 monitoring in maintenance renal transplant recipients: is it worthwhile?","volume":"76","author":"Midtvedt","year":"2003","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0660","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0971-4065.43691","article-title":"Utility of C-2 (cyclosporine) monitoring in postrenal transplant patients: a study in the Indian population","volume":"18","author":"Thakur","year":"2008","journal-title":"Indian J. Nephrol."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0665","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0041-1345(96)00320-X","article-title":"Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients: a prospective randomized study","volume":"29","author":"Cantarovich","year":"1997","journal-title":"Transplant. Proc."},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0670","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00007890-199001000-00007","article-title":"The impact of steady-state cyclosporine concentrations on renal allograft outcome","volume":"49","author":"Dunn","year":"1990","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0675","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1208\/s12248-013-9500-8","article-title":"Population pharmacokinetics of cyclosporine in transplant recipients","volume":"15","author":"Han","year":"2013","journal-title":"AAPS J."},{"issue":"11","key":"10.1016\/j.trim.2024.102147_bb0680","first-page":"1287","article-title":"Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides","volume":"4","author":"Serkova","year":"2003","journal-title":"Curr. Opin. Investig. Drugs (London, England: 2000)"},{"issue":"1","key":"10.1016\/j.trim.2024.102147_bb0685","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s40800-015-0023-3","article-title":"Accidental overdose of oral cyclosporine in haematopoietic stem cell transplantation: a case report and literature review","volume":"2","author":"Tafazoli","year":"2015","journal-title":"Drug Saf. Case Rep."},{"issue":"22","key":"10.1016\/j.trim.2024.102147_bb0690","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.3390\/molecules27227771","article-title":"Natural reno-protective agents against cyclosporine A-induced nephrotoxicity: an overview","volume":"27","author":"Ibrahim","year":"2022","journal-title":"Molecules"},{"issue":"11\u221212","key":"10.1016\/j.trim.2024.102147_bb0695","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/j.1552-4604.1984.tb02763.x","article-title":"The clearance of cyclosporine by hemodialysis","volume":"24","author":"Venkataramanan","year":"1984","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0700","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.healun.2005.11.440","article-title":"Successful whole blood exchange by apheresis in a patient with acute cyclosporine intoxication without long-term sequelae","volume":"25","author":"Kwon","year":"2006","journal-title":"J. Heart Lung Transplant."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0705","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2125.2010.03689.x","article-title":"Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose","volume":"70","author":"Klawitter","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0710","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007890-199608150-00002","article-title":"Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model","volume":"62","author":"Andoh","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2024.102147_bb0715","series-title":"Unexpected Overdose of Oral Cyclosporine in a Kidney Transplant Patient: A Case Report","first-page":"242","volume":"30(4)","author":"Bacle","year":"2023"},{"issue":"3","key":"10.1016\/j.trim.2024.102147_bb0720","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1345\/aph.19134","article-title":"Atrial fibrillation following acute overdose with oral cyclosporine","volume":"34","author":"LoVecchio","year":"2000","journal-title":"Ann. Pharmacother."},{"issue":"8436","key":"10.1016\/j.trim.2024.102147_bb0725","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(85)91660-5","article-title":"Activated charcoal in acute cyclosporin overdose","volume":"1","author":"Honcharik","year":"1985","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.trim.2024.102147_bb0730","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev.me.37.020186.001243","article-title":"Action and toxicity of cyclosporine","volume":"37","author":"Bennett","year":"1986","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.trim.2024.102147_bb0735","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/vec.12694","article-title":"Treatment of acute kidney injury associated with cyclosporine overdose in a dog using hemodialysis and charcoal hemoperfusion","volume":"28","author":"Segev","year":"2018","journal-title":"J. Vet. Emerg. Crit. Care (San Antonio)"},{"issue":"5","key":"10.1016\/j.trim.2024.102147_bb0740","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00003088-200038050-00004","article-title":"Methods for clinical monitoring of cyclosporin in transplant patients","volume":"38","author":"Dumont","year":"2000","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.trim.2024.102147_bb0745","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s10792-021-01708-1","article-title":"Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren\u2019s syndrome versus non-Sjogren\u2019s syndrome","volume":"41","author":"Cubuk","year":"2021","journal-title":"Int. Ophthalmol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424001631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424001631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T11:09:43Z","timestamp":1739099383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327424001631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":149,"alternative-id":["S0966327424001631"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2024.102147","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporine: Immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2024.102147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102147"}}